Sysmex (OTCMKTS:SSMXY) Issues FY 2026 Earnings Guidance

Sysmex (OTCMKTS:SSMXY – Get Free Report) issued an update on its FY 2026 earnings guidance on Friday. The company provided earnings per share guidance of 0.382-0.382 for the period, compared to the consensus EPS estimate of 0.440. The company issued revenue guidance of $3.4 billion-$3.4 billion, compared to the consensus revenue estimate of $3.1 billion.

Wall Street Analysts Forecast Growth

Separately, Zacks Research downgraded shares of Sysmex from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold”.

Get Sysmex alerts:

Read Our Latest Research Report on Sysmex

Sysmex Stock Up 6.2%

SSMXY opened at $10.94 on Friday. Sysmex has a 12 month low of $8.01 and a 12 month high of $14.20. The business has a 50-day moving average of $9.38 and a two-hundred day moving average of $9.08. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.26 and a quick ratio of 2.46. The stock has a market capitalization of $6.89 billion, a price-to-earnings ratio of 28.79 and a beta of 1.05.

Sysmex (OTCMKTS:SSMXY – Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.07 by $0.02. Sysmex had a net margin of 7.13% and a return on equity of 7.23%. The business had revenue of $825.85 million for the quarter, compared to analyst estimates of $739.25 million. Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS. On average, research analysts expect that Sysmex will post 0.42 earnings per share for the current year.

About Sysmex

(Get Free Report)

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.

Featured Stories

• Five stocks we like better than Sysmex
• Why These 3 Equal Weight ETFs Have Outperformed the S&P This Year
• MarketBeat Week in Review – 08/03 – 08/07
• Datadog’s Drop Says More About Expectations Than Earnings
• D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off

Receive News & Ratings for Sysmex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sysmex and related companies with MarketBeat.com's FREE daily email newsletter.